Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International



Home > Press > Mimetic Solutions Chooses UK for Smart-release Drug Lab

Abstract:
Mimetic Solutions LLC has chosen the University of Kentucky's on-campus business incubator, the Advanced Science and Technology Commercialization Center (ASTeCC), as the location for its research and development lab in smart-release drug-delivery technology.

Mimetic Solutions Chooses UK for Smart-release Drug Lab

LEXINGTON, KY | Posted on May 23rd, 2007

Mimetic Solutions is a biopharmaceutical startup that focuses on smart-release chemistry, including finely tuned drug and chemical releases in response to specific biomarkers. The first application of the technology likely will be smart release of insulin in response to blood glucose levels in diabetic patients.

Brian Windsor, managing director of Mimetic Solutions, attributed the selection of UK to "the state-of-the-art facilities and the scientific environment the University of Kentucky offers."

The company's R&D lab in ASTeCC will be headed by UK chemical engineering assistant professor Zach Hilt and University of Texas at Austin chemical engineering professor Nicholas Peppas. Hilt and Peppas worked on the core technology on which Mimetic is based. They are co-editors of one of the first nanotechnology books in the field of therapeutic drug delivery. Mimetic is managed and funded by Emergent Technologies Inc. of Austin, Texas.

"Mimetic Solutions is at the forefront of the growing field of smart polymer chemistry. Our work will focus on drug delivery using our core Affinimer™ technology, which involves smart polymers that are engineered to release active agents as a result of binding specific bioactive markers, such as the delivery of a therapeutic in response to a key biomarker in a patient's blood," Hilt said.

"There's no question that Mimetic Solutions is a great fit with UK's goal to be a catalyst for faculty startups and new businesses using UK technology. We not only provide incubator space, but we also provide the kinds of business structure support and expertise that are essential in successfully launching a new company," said Len Heller, UK's vice president for commercialization and economic development.

UK President Lee T. Todd Jr. expressed enthusiasm regarding Mimetic Solutions coming to ASTeCC. "UK has been a leader in pharmaceutical advances for decades, and Mimetic Solutions' presence here demonstrates the increasing recognition of our commitment to being an economic engine behind the growth of the knowledge-based economy in Kentucky," Todd said.

####

About ASTeCC
The Advanced Science and Technology Commercialization Center, better known as ASTeCC, is the University of Kentucky's showplace for multidisciplinary research, technology transfer, and new business startups. ASTeCC is a combination faculty research facility and commercialization center.

The ASTeCC building, located in the heart of the UK campus, features two types of lab space -- faculty labs and labs for business startups that have a connection to UK faculty or staff, or that have licensed UK intellectual property. Faculty with labs in ASTeCC represent colleges throughout the university, and faculty all across campus use ASTeCC as a hub for tech-transfer activities. ASTeCC also houses a number of shared research and support resources for the entire UK community.

The $17 million, 80,000-square-foot ASTeCC building opened its doors in 1994. The project was funded by the U.S. Economic Development Administration and the Small Business Administration.

For more information, please click here

Contacts:
Dan Adkins
(859) 257-1754

Copyright © University of Kentucky

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Nanomedicine

Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024

NYU Abu Dhabi researchers develop novel covalent organic frameworks for precise cancer treatment delivery: NYU Abu Dhabi researchers develop novel covalent organic frameworks for precise cancer treatment delivery September 13th, 2024

Unveiling the power of hot carriers in plasmonic nanostructures August 16th, 2024

Nanobody inhibits metastasis of breast tumor cells to lung in mice: “In the present study we describe the development of an inhibitory nanobody directed against an extracellular epitope present in the native V-ATPase c subunit.” August 16th, 2024

Announcements

Nanotechnology: Flexible biosensors with modular design November 8th, 2024

Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024

Turning up the signal November 8th, 2024

Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project